Uniqure NV (QURE) Given Consensus Rating of “Buy” by Brokerages

Share on StockTwits

Shares of Uniqure NV (NASDAQ:QURE) have been given an average rating of “Buy” by the thirteen brokerages that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $74.00.

A number of analysts recently issued reports on QURE shares. B. Riley started coverage on Uniqure in a report on Monday, December 31st. They issued a “buy” rating and a $72.00 price target for the company. Guggenheim started coverage on Uniqure in a report on Monday, December 17th. They issued a “buy” rating and a $35.00 price target for the company. HC Wainwright set a $60.00 price target on Uniqure and gave the company a “buy” rating in a report on Tuesday, December 4th. Chardan Capital reiterated a “buy” rating and issued a $70.00 price target on shares of Uniqure in a report on Monday, December 3rd. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $68.00 price target on shares of Uniqure in a report on Friday, February 8th.

In other Uniqure news, SVP Alexander Edward Kuta III sold 1,052 shares of the company’s stock in a transaction on Monday, January 28th. The stock was sold at an average price of $31.29, for a total transaction of $32,917.08. Following the completion of the sale, the senior vice president now owns 26,578 shares in the company, valued at $831,625.62. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Matthew C. Kapusta sold 67,376 shares of the stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $63.96, for a total value of $4,309,368.96. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 113,390 shares of company stock valued at $5,764,148. 1.56% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently modified their holdings of QURE. Federated Investors Inc. PA lifted its holdings in shares of Uniqure by 43.5% during the 3rd quarter. Federated Investors Inc. PA now owns 1,565,600 shares of the biotechnology company’s stock valued at $56,972,000 after purchasing an additional 474,320 shares during the last quarter. 683 Capital Management LLC lifted its holdings in shares of Uniqure by 10.3% during the 4th quarter. 683 Capital Management LLC now owns 1,085,000 shares of the biotechnology company’s stock valued at $31,270,000 after purchasing an additional 100,900 shares during the last quarter. Alps Advisors Inc. purchased a new stake in shares of Uniqure during the 4th quarter valued at $2,460,000. Henry James International Management Inc. purchased a new stake in shares of Uniqure during the 3rd quarter valued at $2,852,000. Finally, Franklin Resources Inc. lifted its holdings in shares of Uniqure by 27.8% during the 3rd quarter. Franklin Resources Inc. now owns 311,300 shares of the biotechnology company’s stock valued at $11,328,000 after purchasing an additional 67,800 shares during the last quarter. Hedge funds and other institutional investors own 61.16% of the company’s stock.

Shares of QURE traded down $0.20 during mid-day trading on Friday, reaching $63.35. 592,006 shares of the company’s stock traded hands, compared to its average volume of 534,900. The stock has a market cap of $2.44 billion, a price-to-earnings ratio of -27.07 and a beta of 1.07. Uniqure has a 12 month low of $20.29 and a 12 month high of $67.93. The company has a debt-to-equity ratio of 0.20, a quick ratio of 11.85 and a current ratio of 11.85.

Uniqure (NASDAQ:QURE) last released its earnings results on Thursday, February 28th. The biotechnology company reported ($0.59) EPS for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.08. Uniqure had a negative return on equity of 47.73% and a negative net margin of 738.25%. As a group, analysts predict that Uniqure will post -2.8 earnings per share for the current fiscal year.

Uniqure Company Profile

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease.

Featured Article: How are institutional investors different from individual investors?

Analyst Recommendations for Uniqure (NASDAQ:QURE)

Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.